

Special Issue

Advances in Treatment of Urinary Bladder Cancer

Message from the Guest Editor

Urinary bladder cancer is among the top ten most common cancer types in the world, with approximately 550,000 new cases annually. At present, 75% of cases are non-muscle-invasive bladder cancer (NMIBC), and the others are muscle-invasive (MIBC), a progression from the first kind. The identification of targets and potential biomarkers based on genomic sequencing analyses can also be useful for predicting the response of novel therapeutic strategies. Therapy has in recent years evolved from surgery to oncological combination therapies, and more recently, immunotherapeutic strategies have been added to the treatment arsenal. This Special Issue aims to present new and innovative approaches and results relating to basic science, translational research, and epidemiology in the field of urinary bladder cancer. The scope entails studies on non-muscle-invasive urinary bladder cancer (NMIBC) as well as those on muscle invasive urinary bladder cancer (MIBC) and papers investigating molecular biomarkers' response to treatment and radiomics to improve staging in urinary bladder cancer. We welcome original articles and review papers.

Guest Editor

Dr. Amir M. Sherif

Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, 901 85 Umeå, Sweden

Deadline for manuscript submissions

closed (15 May 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/149060

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).